High craving is associated with fewer abstinent days and lesser time to relapse during treatment in severe alcohol use disorder

在严重酒精使用障碍的治疗过程中,强烈的渴求与较少的戒酒天数和较短的复发时间相关。

阅读:1

Abstract

BACKGROUND: Craving, an integral aspect of addictive processes, underlies heavy alcohol consumption and alcohol use disorder (AUD). Western studies point out that craving is associated with relapse risks in AUD treatment. The feasibility of assessing and following up with craving dynamicity is not studied in the Indian context. AIM: We aimed to capture craving and explore its association with relapse in an outpatient facility. METHODS: Among 264 treatment-seeking male participants (mean [SD] age = 36 [6.7] years) with severe AUD, craving was assessed according to the Penn Alcohol Craving Scale (PACS) at treatment initiation and two follow-up visits (median follow-up: 1, 2 weeks). Days to drink and percentage of days abstinent were acquired during the follow-ups (maximum follow-up days = 355). Those lost to follow-up were censored and considered as having relapsed. RESULTS: High craving was associated with fewer days to drink when considered as a sole predictor (P = 0.030). With covariates including medication at treatment initiation, high craving was marginally associated with fewer days to drink (P = 0.057). Baseline craving was negatively associated with proximal percentage of days abstinent (P = 0.015) and cravings at follow-ups negatively correlated with cross-sectional abstinent days (FU1: P = 0.009, FU2: P = 0.019). Craving reduced significantly over time (P < 0.001), irrespective of the drinking status in follow-ups. CONCLUSION: Relapse is a real challenge in AUD. The utility of craving assessment in identifying relapse risk in an outpatient facility helps in identifying an at-risk population for future relapse. Thus better-targeted approaches in treating AUD can be developed.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。